Reasonably good Q2, despite underlying challenges/risks
13/05/22 -"Despite the supply-chain challenges, CZM reported a reasonably good set of Q2 21/22 results. Both segments reported double-digit growth and order intake was impressive. Unlike most of the MedTech ..."
Pages
60
Language
English
Published on
13/05/22
You may also be interested by these reports :
28/01/26
Getinge reported a soft Q4, with net sales and adjusted EBITA missing expectations and organic growth slowing to 1.2%. Order momentum also eased, ...
22/01/26
CZM’s Q1 FY 2025-26 preliminary release fell short of market expectations. Sales and profitability were adversely affected by both external and ...
19/01/26
Drägerwerk has delivered solid FY25 preliminary numbers. The key surprise was EBIT, which beat consensus by c.18%, reflecting better gross margins ...
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...